- Home
- CTXR vs FLUX Comparison
CTXR vs FLUX Comparison
Compare CTXR & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTXR | FLUX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 24.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CTXR | FLUX |
|---|---|---|
| Price | $0.71 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 491.0K | 227.4K |
| Earning Date | 02-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,944,111.00 | ★ $60,775,000.00 |
| Revenue This Year | N/A | $0.18 |
| Revenue Next Year | $147.57 | $29.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.02 |
| 52 Week High | $2.97 | $7.55 |
Technical Indicators
Market Signals| Indicator | CTXR | FLUX |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 35.78 |
| Support Level | $0.70 | $1.25 |
| Resistance Level | $0.95 | $1.47 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 10.92 | 5.96 |
Price Performance
Historical ComparisonAbout CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.